80761-61-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Quinolinecarbonyl chloride, 1,4-dihydro-4-oxo(9CI) is used as a key intermediate in the synthesis of Ivacaftor Carboxylic Acid (I940605), a compound that plays a crucial role in the development of Ivacaftor (I940600). Ivacaftor is a medication used for the treatment of cystic fibrosis, a genetic disorder that affects the lungs and digestive system. 3-Quinolinecarbonyl chloride, 1,4-dihydro-4-oxo(9CI) helps in modulating the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, thereby improving the symptoms and quality of life for patients with specific CFTR gene mutations.
Additionally, 3-Quinolinecarbonyl chloride, 1,4-dihydro-4-oxo(9CI) may also be utilized in the synthesis of other pharmaceutical agents, given its reactivity and potential to form a variety of chemical linkages. Its applications in drug discovery and development can contribute to the advancement of new therapeutics for various diseases and conditions.

Upstream product

• 13721-01-2 4-oxo-1,4-dihydroquinoline-3-carboxylic acid 

Downstream Products

• 873050-50-1 4-oxo-1,4-dihydroquinoline-3-carboxylic acid (1H-indol-6-yl)amide 
• 873054-36-5 N-(4-isopropylphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 
• 873054-73-0 N-(4-ethylphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 
• 857208-58-3 4-oxo-1,4-dihydroquinoline-3-carboxylic acid phenylamide 

Relevant academic research and scientific papers

Quinolone-based oxazolidinone compound as well as preparation method and application thereof

The invention discloses a quinolone-based oxazolidinone compound with a formula (HB), a solvate thereof, a stereoisomer of the compound, or a pharmaceutically acceptable salt of the compound, a preparation method of the compound and application of the com

SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES

The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.

Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a potent and orally bioavailable CFTR potentiator

Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.

Syntheses and Reactions of Diazepinoquinolines

Three routes for the preparation of diazepinoquinolines (1) have been studied.The best yields resulted by starting from the amides of N-(3-quinolylcarbonyl)-N-alkyl-amino acids (5).Quaternization to 9, intramolecular cyclization under the influence of base to 10, oxidation to 11 and debenzylation by catalytic hydrogenation gave 1. - Keywords: Quinolinium Salts, Cyclization Reaction